Excellthera Inc.
Clinical trials sponsored by Excellthera Inc., explained in plain language.
-
Breakthrough cord blood treatment shows promise for tough blood cancers
Disease control CompletedThis study tested a new method to improve cord blood transplants for patients with high-risk leukemia or myelodysplasia who lack a perfect donor match. Researchers used a molecule called UM171 to expand the number of stem cells in cord blood before transplant, aiming to make the …
Phase: PHASE2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Apr 02, 2026 13:43 UTC
-
New hope for young blood cancer patients: supercharged cord blood transplants show promise
Disease control CompletedThis study tested a new method to improve cord blood transplants for children and young adults (under 21) with very high-risk blood cancers like leukemia. Researchers used a molecule called UM171 to 'expand' or grow more cells from a cord blood donation before transplant, aiming …
Phase: PHASE1, PHASE2 • Sponsor: ExCellThera inc. • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC